Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cyclopharm Limited ( (AU:CYC) ) just unveiled an update.
Cyclopharm Limited has announced a change in the director’s interest, with Director David James Heaney acquiring 8,874 ordinary shares through an on-market trade, increasing his total holdings to 310,000 shares. This change in shareholding reflects a continued confidence in the company’s growth prospects and may influence investor perception positively, potentially impacting the company’s market positioning and stakeholder interests.
More about Cyclopharm Limited
Cyclopharm Limited operates in the healthcare industry, primarily focusing on the development and distribution of medical equipment and pharmaceuticals. The company is known for its specialized products that cater to the needs of the medical imaging sector.
YTD Price Performance: 20.25%
Average Trading Volume: 110,041
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$211.2M
See more data about CYC stock on TipRanks’ Stock Analysis page.